UPDATE: Moderna (MRNA) Prices 26.32M Share Common Offering at $19/Sh

Pre-Open Stock Movers 02/11: (S) (AMKR) (TMUS) Higher; (YAYO) (CODX) (UAA) Lower (more...)

Today's Pre-Open Stock Movers

Sprint (NYSE: S) 72.7% HIGHER; T-Mobile US, Inc. (NASDAQ:... More

After-Hours Stock Movers 2/10: (AMKR) (FLDM) (RNG) Higher; (YAYO) (LOGC) (WORK) Lower (more...)

YayYo, Inc. (NASDAQ: YAYO) 45% LOWER; today announced its intention to voluntarily delist its common stock from the NASDAQ Stock Market (NASDAQ) effective on February 20, 2020. The Company expects that its common stock will be approved for quotation on the OTCQB from and after that date. The Company has elected to effect the voluntary delisting of its common stock after discussions with NASDAQs staff and based on the determination of the Companys board of directors that voluntarily delisting the common stock from the NASDAQ is in the best... More

Moderna (MRNA) Announces Progress in Prophylactic Vaccines Modality

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Phase 2 dose-confirmation study of its mRNA vaccine against cytomegalovirus (CMV) is enrolling ahead of plan with data now expected in the third quarter of 2020. The Company also announced three new vaccine development candidates, which support the Companys strategy, announced January 12, to accelerate new development candidates in its core modalities, prophylactic vaccines and systemic secreted & cell surface therapeutics. The three new infectious disease vaccine candidates... More

Moderna (MRNA) Announces First Patient Enrolled in Phase 1/2 Study of mRNA-3704 for Methylmalonic

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the first patient has been enrolled in the Phase 1/2 study evaluating the safety and tolerability of escalating doses of mRNA-3704 administered via intravenous infusion in patients with isolated methylmalonic acidemia (MMA) due to MUT deficiency. This is Modernas first rare disease program to begin clinical trial enrollment. The patient has entered an observational period prior to treatment, which evaluates the patients baseline... More

Moderna (MRNA) to Offer $500M in Common Stock

Moderna, Inc. (Nasdaq: MRNA) announced that it has commenced an underwritten public offering of $500 million in shares of common stock. In addition, Moderna expects to grant the underwriters a 30-day option to purchase up to an additional $75 million in shares of common stock in... More

Moderna (MRNA) February calls active

Moderna (NASDAQ: MRNA) February call option implied volatility is at 91, March is at 82; compared to its 52-week range of 51 to 99. Call put ratio 16 calls to 1 put with focus on February 22.50 and 25 calls